Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC)

Clinical Lung Cancer

Volumn 13, Issue 4, 2012, Pages 252-266

  Reungwetwattana, Thanyanan ^a,b   Weroha, Saravut J ^b   Molina, Julian R ^b  

^a MAHIDOL UNIVERSITY   (Thailand)

^b MAYO CLINIC   (United States)

Author keywords

EGFR; EML4 ALK; IGF 1R; KRAS; LKB1; Lung cancer; MET; PI3K; Targeted therapies

Indexed keywords

AFATINIB; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CRIZOTINIB; DACOMITINIB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FIGITUMUMAB; GEFITINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN KINASE LKB1; RAF PROTEIN; RAS PROTEIN; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; TIVANTINIB;

ANAPLASTIC LYMPHOMA KINASE GENE; CHROMOSOME 2; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4 GENE; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; ONCOGENE K RAS; REVIEW;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; HUMANS; LUNG NEOPLASMS; MOLECULAR TARGETED THERAPY; MUTATION; SIGNAL TRANSDUCTION; SMOKING;

EID: 84861594994     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.09.004     Document Type: Review

References (117)

1. A. Jemal, R. Siegel, J. Xu, E. Ward Cancer statistics CA Cancer J Clin 60 2010 277 300
2. C.F. Mountain The international system for staging lung cancer Semin Surg Oncol 18 2000 106 115 (Pubitemid 30090451)
3. F. Fossella, J.R. Pereira, J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group J Clin Oncol 21 2003 3016 3024 (Pubitemid 46606280)
4. K. Kelly, J. Crowley, P.A. Bunn Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial J Clin Oncol 19 2001 3210 3218 (Pubitemid 32591438)
5. G.V. Scagliotti, F. De Marinis, M. Rinaldi Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer J Clin Oncol 20 2002 4285 4291 (Pubitemid 35266288)
6. J.H. Schiller, D. Harrington, C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98 (Pubitemid 34438899)
7. E. Cabebe, H. Wakelee Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors Curr Treat Options Oncol 8 2007 15 27
8. T. Ciuleanu, T. Brodowicz, C. Zielinski Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
9. R. Pirker, J.R. Pereira, A. Szczesna Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Lancet 373 2009 1525 1531
10. M. Reck, J. von Pawel, P. Zatloukal Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil J Clin Oncol 27 2009 1227 1234
11. R. Blanco, R. Iwakawa, M. Tang A gene-alteration profile of human lung cancer cell lines Hum Mutat 30 2009 1199 1206
12. D.S. Salomon, R. Brandt, F. Ciardiello Epidermal growth factor-related peptides and their receptors in human malignancies Crit Rev Oncol Hematol 19 1995 183 232
13. S.V. Sharma, D.W. Bell, J. Settleman Epidermal growth factor receptor mutations in lung cancer Nat Rev Cancer 7 2007 169 181
14. F. Blackhall, M. Ranson, N. Thatcher Where next for gefitinib in patients with lung cancer? Lancet Oncol 7 2006 499 507 (Pubitemid 43779172)
15. U. McDermott, S.V. Sharma, L. Dowell Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling Proc Natl Acad Sci U S A 104 2007 19936 19941
16. T.S. Mok, Y.L. Wu, S. Thongprasert Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
17. T. Mok, Y.L. Wu, L. Zhang A small step towards personalized medicine for non-small cell lung cancer Discov Med 8 2009 227 231
18. M. Fukuoka, Y.L. Wu, S. Thongprasert Biomarker analyses and final overall survival results from a phase iii, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS) J Clin Oncol 29 2011 2866 2874
19. J. Lee, K. Park, S. Kim A randomized phase III study of gefitinib versus standard chemotherapy (gemcitabine plus cisplatin) as a first-line treatment for never-smokers with advanced or metastatic adenocarcinoma of the lung Presented at 13th World Conference on Lung Cancer, San Francisco J Thorac Oncol 2009 Abstract PRS 4
20. M. Maemondo, A. Inoue, K. Kobayashi Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
21. T. Mitsudomi, S. Morita, Y. Yatabe Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial Lancet Oncol 11 2010 121 128
22. C. Zhou, Y.L. Wu, G. Chen Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Lancet Oncol 12 2011 735 742 Epub 2011 Jul 23
23. R. Rosell, R. Gervais, A. Vergnenegre Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: interim results of the European Erlotinib Versus Chemotherapy (EURTAC) phase III randomized trial J Clin Oncol 29 suppl 2011 abstract 7503 www.asco.org Accessed: October 11, 2011
24. C.G. Azzoli, S. Baker Jr, S. Temin American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer J Clin Oncol 27 2009 6251 6266
25. E.M. Ibrahim, K.M. Abouelkhair, O.A. Al-Masri Cetuximab-based therapy is effective in chemotherapy-naive patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials Lung 189 2011 193 198
26. P. Chen, L. Wang, B. Liu EGFR-targeted therapies combined with chemotherapy for treating advanced non-small-cell lung cancer: a meta-analysis Eur J Clin Pharmacol 67 2011 235 243
27. NCCN Practice Guideline in Non-Small Cell Lung Cancer 2011 http://www.nccn.org/professionals/physician-gls/f-guidelines.asp Accessed: January 3, 2011
28. K. O'Byrne, I. Bondarenko, C. Barrios Molecular and clinical predictors of outcome for cetuximab in non-small cell lung cancer (NSCLC): data from the FLEX study J Clin Oncol 27 15suppl 2009 abstract 8007 www.asco.org Accessed: October 11, 2011
29. F. Cappuzzo, T. Ciuleanu, L. Stelmakh Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
30. K. Takeda, T. Hida, T. Sato Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-small-cell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203) J Clin Oncol 28 2010 753 760
31. V.A. Miller, P. O'Connor, C. Soh A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 27 15suppl 2009 abstract 8002 www.asco.org Accessed: October 11, 2011
32. F.A. Shepherd, J. Rodrigues Pereira, T. Ciuleanu Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132 (Pubitemid 41058344)
33. N. Thatcher, A. Chang, P. Parikh Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 2005 1527 1537 (Pubitemid 41540110)
34. F. Cappuzzo, F.R. Hirsch, E. Rossi Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer J Natl Cancer Inst 97 2005 643 655 (Pubitemid 40812628)
35. M.S. Tsao, A. Sakurada, J.C. Cutz Erlotinib in lung cancer - molecular and clinical predictors of outcome N Engl J Med 353 2005 133 144 (Pubitemid 41058345)
36. E.S. Kim, V. Hirsh, T. Mok Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial Lancet 372 2008 1809 1818
37. W. Pao, V. Miller, M. Zakowski EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 2004 13306 13311 (Pubitemid 39209661)
38. M. Tokumo, S. Toyooka, K. Kiura The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers Clin Cancer Res 11 2005 1167 1173 (Pubitemid 40175767)
39. F. Ciardiello, G. Tortora EGFR antagonists in cancer treatment N Engl J Med 358 2008 1160 1174
40. X. Zhang, J. Gureasko, K. Shen An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 2006 1137 1149 (Pubitemid 43866200)
41. A. Kumar, E.T. Petri, B. Halmos Structure and clinical relevance of the epidermal growth factor receptor in human cancer J Clin Oncol 26 2008 1742 1751
42. K.D. Carey, A.J. Garton, M.S. Romero Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib Cancer Res 66 2006 8163 8171 (Pubitemid 44299184)
43. L.V. Sequist, R.G. Martins, D. Spigel First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations J Clin Oncol 26 2008 2442 2449
44. I.J. Dahabreh, H. Linardou, F. Siannis Somatic EGFR mutation and gene copy gain as predictive biomarkers for response to tyrosine kinase inhibitors in non-small cell lung cancer Clin Cancer Res 16 2010 291 303
45. S. Kobayashi, T.J. Boggon, T. Dayaram EGFR mutation and resistance of non-small-cell lung cancer to gefitinib N Engl J Med 352 2005 786 792 (Pubitemid 40271173)
46. J. Bean, C. Brennan, J.Y. Shih MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib Proc Natl Acad Sci U S A 104 2007 20932 20937
47. F. Cappuzzo, A. Marchetti, M. Skokan Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients J Clin Oncol 27 2009 1667 1674
48. M. Nomura, H. Shigematsu, L. Li Polymorphisms, mutations, and amplification of the EGFR gene in non-small cell lung cancers PLoS Med 4 2007 e125
49. Y. Yatabe, T. Takahashi, T. Mitsudomi Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer Cancer Res 68 2008 2106 2111 (Pubitemid 351521782)
50. F.R. Hirsch, M. Varella-Garcia, P.A. Bunn Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer J Clin Oncol 24 2006 5034 5042 (Pubitemid 46631407)
51. F.R. Hirsch, M. Varella-Garcia, R. Dziadziuszko Fluorescence in situ hybridization subgroup analysis of TRIBUTE, a phase III trial of erlotinib plus carboplatin and paclitaxel in non-small cell lung cancer Clin Cancer Res 14 2008 6317 6323
52. U. Gatzemeier, A. Pluzanska, A. Szczesna Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 2007 1545 1552 (Pubitemid 46733081)
53. J.M. Amann, J.W. Lee, H. Roder Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503 J Thorac Oncol 5 2010 169 178
54. C. Yang, J. Shih, W. Su A phase II study of BIBW 2992, in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung2) J Clin Oncol 28 15suppl 2010 abstract 7521 www.asco.org Accessed: October 11, 2011
55. V.A. Miller, V. Hirsh, J. Cadranel Phase 2b/3 double-blind randomized trial of afatinib (BIBW2992, an irreversible inhibitor of EGFR/HER1 and HER2) + best supportive care (BSC) versus placebo + BSC in patients with NSCLC failing 1-2 lines of chemotherapy and erlotinib or gefitinib (LUX-Lung 1) Ann Oncol 21 suppl8 2010 viii1-viii: abstract LBA1
56. Y.Y. Janjigian, H.J. Groen, L. Horn Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib J Clin Oncol 29 suppl 2011 abstract 7525
57. P.A. Janne, K. Reckamp, M. Koczywas Efficacy and safety of PF-00299804 (PF299) in patients with advanced NSCLC after failure of at least one prior chemotherapy regimen and prior treatment with erlotinib (E): a two-arm, phase II trial J Clin Oncol 27 suppl 2009 abstract 8063 www.asco.org Accessed: October 11, 2011
58. C.H. Yun, K.E. Mengwasser, A.V. Toms The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci U S A 105 2008 2070 2075 (Pubitemid 351439466)
59. R. Khosravi-Far, C.J. Der The Ras signal transduction pathway Cancer Metastasis Rev 13 1994 67 89 (Pubitemid 24053340)
60. B. Margolis, E.Y. Skolnik Activation of Ras by receptor tyrosine kinases J Am Soc Nephrol 5 1994 1288 1299 (Pubitemid 24977112)
61. J. Avruch, A. Khokhlatchev, J.M. Kyriakis Ras activation of the Raf kinase: tyrosine kinase recruitment of the MAP kinase cascade Recent Prog Horm Res 56 2001 127 155
62. C. Montagut, J. Settleman Targeting the RAF-MEK-ERK pathway in cancer therapy Cancer Lett 283 2009 125 134
63. M.S. Brose, P. Volpe, M. Feldman BRAF and RAS mutations in human lung cancer and melanoma Cancer Res 62 2002 6997 7000 (Pubitemid 35424092)
64. M. Li, L. Liu, Z. Liu The status of KRAS mutations in patients with non-small cell lung cancers from mainland China Oncol Rep 22 2009 1013 1020
65. C. Mao, L.X. Qiu, R.Y. Liao KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies Lung Cancer 69 2010 272 278
66. R.J. Slebos, R.E. Kibbelaar, O. Dalesio K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung N Engl J Med 323 1990 561 565 (Pubitemid 20260082)
67. C. Mascaux, N. Iannino, B. Martin The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis Br J Cancer 92 2005 131 139 (Pubitemid 40188446)
68. M.S. Tsao, S. Aviel-Ronen, K. Ding Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer J Clin Oncol 25 2007 5240 5247 (Pubitemid 350232256)
69. D.A. Eberhard, B.E. Johnson, L.C. Amler Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib J Clin Oncol 23 2005 5900 5909
70. W. Brugger, N. Triller, M. Blasinska-Morawiec Biomarker analyses from the phase III placebo-controlled SATURN study of maintenance erlotinib following first-line chemotherapy for advanced NSCLC J Clin Oncol 27 15suppl 2009 abstract 8020 www.asco.org Accessed: October 11, 2011
71. C.Q. Zhu, G. da Cunha Santos, K. Ding Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21 J Clin Oncol 26 2008 4268 4275
72. M.C. Garassino, K. Borgonovo, A. Rossi Biological and clinical features in predicting efficacy of epidermal growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis Anticancer Res 29 2009 2691 2701
73. A.N. Hughes, M.E. O'Brien, W.J. Petty Overcoming CYP1A1/1A2 mediated induction of metabolism by escalating erlotinib dose in current smokers J Clin Oncol 27 2009 1220 1226
74. P.E. Burnett, R.K. Barrow, N.A. Cohen RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1 Proc Natl Acad Sci U S A 95 1998 1432 1437 (Pubitemid 28103409)
75. A. Carnero, C. Blanco-Aparicio, O. Renner The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications Curr Cancer Drug Targets 8 2008 187 198 (Pubitemid 351688437)
76. J.M. Tang, Q.Y. He, R.X. Guo Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis Lung Cancer 51 2006 181 191
77. J.A. Fresno Vara, E. Casado, J. de Castro PI3K/Akt signalling pathway and cancer Cancer Treat Rev 30 2004 193 204
78. O. Kawano, H. Sasaki, K. Endo PIK3CA mutation status in Japanese lung cancer patients Lung Cancer 54 2006 209 215 (Pubitemid 44764916)
79. O. Kawano, H. Sasaki, K. Okuda PIK3CA gene amplification in Japanese non-small cell lung cancer Lung Cancer 58 2007 159 160 (Pubitemid 47379973)
80. J.C. Soria, F.A. Shepherd, J.Y. Douillard Efficacy of everolimus (RAD001) in patients with advanced NSCLC previously treated with chemotherapy alone or with chemotherapy and EGFR inhibitors Ann Oncol 20 2009 1674 1681
81. J.R. Molina, S. Mandrekar, K. Rowland A phase II NCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC J Thorac Oncol 2 2007 s413
82. N.T. Ihle, R. Lemos Jr, P. Wipf Mutations in the phosphatidylinositol-3- kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance Cancer Res 69 2009 143 150
83. N.T. Ihle, R. Williams, S. Chow Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling Mol Cancer Ther 3 2004 763 772 (Pubitemid 39193758)
84. T. Iwahara, J. Fujimoto, D. Wen Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system Oncogene 14 1997 439 449 (Pubitemid 27087107)
85. S.W. Morris, M.N. Kirstein, M.B. Valentine Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma Science 263 1994 1281 1284 (Pubitemid 24107549)
86. M. Soda, Y.L. Choi, M. Enomoto Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566 (Pubitemid 47206930)
87. H.M. Amin, R. Lai Pathobiology of ALK+ anaplastic large-cell lymphoma Blood 110 2007 2259 2267 (Pubitemid 47523143)
88. K. Inamura, K. Takeuchi, Y. Togashi EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers J Thorac Oncol 3 2008 13 17
89. A.T. Shaw, B.Y. Yeap, M. Mino-Kenudson Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK J Clin Oncol 27 2009 4247 4253
90. A.T. Shaw, D. Costa, A.J. Iafrate Clinical activity of the oral ALK and MET inhibitor PF-02341066 in non-small cell lung cancer (NSCLC) with EML4-ALK translocations J Thorac Oncol 4 2009 S305 S306
91. E.L. Kwak, Y.J. Bang, D.R. Camidge Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
92. D.R. Camidge, Y. Bang, E.L. Kwak Progression-free survival (PFS) from a phase I study of crizotinib (PF-02341066) in patients with ALK-positive non-small cell lung cancer (NSCLC) J Clin Oncol 29 15suppl 2011 abstract 2501 www.asco.org Accessed: October 11, 2011
93. L. Crino, D. Kim, G.J. Riely Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC): PROFILE 1005 J Clin Oncol 29 15suppl 2011 abstract 7514 www.asco.org Accessed: October 10, 2011
94. P.V. Danenberg, C. Stephens, J. Cook A novel RT-PCR approach to detecting EML4-ALK fusion genes in archival NSCLC tissue J Clin Oncol 28 15suppl 2010 abstract 10535 www.asco.org Accessed: October 10, 2011
95. M. Mino-Kenudson, L.R. Chirieac, K. Law A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry Clin Cancer Res 16 2010 1561 1571
96. E.S. Yi, J.M. Boland, J.J. Maleszewski Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH J Thorac Oncol 6 2011 459 465
97. N.A. Cipriani, O.O. Abidoye, E. Vokes MET as a target for treatment of chest tumors Lung Cancer 63 2009 169 179
98. M. Jeffers, S. Rong, G.F. Woude Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis J Mol Med 74 1996 505 513 (Pubitemid 26306792)
99. F. Bussolino, M.F. Di Renzo, M. Ziche Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth J Cell Biol 119 1992 629 641
100. L. Faoro, G.M. Cervantes, E. El-Hashani MET receptor tyrosine kinase J Thorac Oncol 4 11 suppl 3 2009 S1064 S1065
101. C. Birchmeier, W. Birchmeier, E. Gherardi Met, metastasis, motility and more Nat Rev Mol Cell Biol 4 2003 915 925 (Pubitemid 37493640)
102. J.A. Engelman, K. Zejnullahu, T. Mitsudomi MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
103. J.H. Schiller, W.L. Akerley, W. Brugger Results from ARQ 197-209: a global randomized placebo-controlled phase II clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR inhibitor-naive patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) J Clin Oncol 28 18suppl 2010 abstract LBA7502 www.asco.org Accessed: October 10, 2011
104. D.R. Alessi, K. Sakamoto, J.R. Bayascas LKB1-dependent signaling pathways Annu Rev Biochem 75 2006 137 163 (Pubitemid 44118029)
105. C.I. Amos, D. Bali, T.J. Thiel Fine mapping of a genetic locus for Peutz-Jeghers syndrome on chromosome 19p Cancer Res 57 1997 3653 3656 (Pubitemid 27381201)
106. L.A. Boardman, S.N. Thibodeau, D.J. Schaid Increased risk for cancer in patients with the Peutz-Jeghers syndrome Ann Intern Med 128 1998 896 899 (Pubitemid 28289483)
107. L. Ding, G. Getz, D.A. Wheeler Somatic mutations affect key pathways in lung adenocarcinoma Nature 455 2008 1069 1075
108. S. Matsumoto, R. Iwakawa, K. Takahashi Prevalence and specificity of LKB1 genetic alterations in lung cancers Oncogene 26 2007 5911 5918
109. M. Sanchez-Cespedes, P. Parrella, M. Esteller Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung Cancer Res 62 2002 3659 3662 (Pubitemid 34728843)
110. H. Ji, M.R. Ramsey, D.N. Hayes LKB1 modulates lung cancer differentiation and metastasis Nature 448 2007 807 810 (Pubitemid 47266337)
111. J.P. Koivunen, J. Kim, J. Lee Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients Br J Cancer 99 2008 245 252
112. J. Carretero, T. Shimamura, K. Rikova Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors Cancer Cell 17 2010 547 559
113. H. Werner, D. Le Roith New concepts in regulation and function of the insulin-like growth factors: implications for understanding normal growth and neoplasia Cell Mol Life Sci 57 2000 932 942 (Pubitemid 30461834)
114. M. Pollak Insulin and insulin-like growth factor signalling in neoplasia Nat Rev Cancer 8 2008 915 928
115. D.D. Karp, L.G. Paz-Ares, S. Novello Phase II study of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small-cell lung cancer J Clin Oncol 27 2009 2516 2522
116. J. Jassem, C.J. Langer, D.D. Karp Randomized, open label, phase III trial of figitumumab in combinations with paclitaxel and carboplatin versus paclitaxel and carboplatin in patients with non-small cell lung cancer (NSCLC) J Clin Oncol 28 15suppl 2010 abstract 7500 www.asco.org Accessed: October 11, 2011
117. A. Belfiore, F. Frasca, G. Pandini Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease Endocr Rev 30 2009 586 623